SCHEMBL649156

SCHEMBL649156

CCCCn1c(-c2ccccc2)nc(-c2ccccc2)c1CN(Cc1ccc(OC)cc1)Cc1cccc(OC(F)F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.42
CALM1 P0DP23 1/20 0.38
CAMKK2 Q96RR4 1/20 0.38
NR1H3 Q13133 2/20 0.37
TLR7 Q9NYK1 1/20 0.37
MEP1B Q16820 1/20 0.36
CNR2 P34972 1/20 0.36
PDE4B Q07343 1/20 0.35
ALDH1A1 P00352 3/20 0.35
HTT P42858 2/20 0.35
PPARG P37231 2/20 0.35
PPARA Q07869 2/20 0.35
TSHR P16473 3/20 0.35
NPSR1 Q6W5P4 2/20 0.35
KDM4E B2RXH2 1/20 0.35
LMNA P02545 1/20 0.35
GAA P10253 1/20 0.35
MAPT P10636 2/20 0.34
RXFP1 Q9HBX9 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648790 0.96 C5AR1 (0.43) C5AR1MEP1BALDH1A1HTTPPARG
SCHEMBL648222 0.95 C5AR1 (0.43) C5AR1CALM1CAMKK2MEP1BPDE4B
SCHEMBL652475 0.94 C5AR1 (0.39) C5AR1CALM1CAMKK2NR1H3TLR7
SCHEMBL5135971 0.93 C5AR1 (0.41) C5AR1CNR2PDE4BALDH1A1HTT
SCHEMBL1913032 0.92 C5AR1 (0.41) C5AR1CNR2PDE4BALDH1A1HTT
SCHEMBL648419 0.92 C5AR1 (0.46) C5AR1CALM1CAMKK2NR1H3TLR7
SCHEMBL648977 0.92 C5AR1 (0.41) C5AR1NR1H3TLR7ALDH1A1HTT
SCHEMBL648415 0.92 TLR7 (0.40) C5AR1NR1H3TLR7PDE4BMAPT
SCHEMBL652216 0.91 C5AR1 (0.42) C5AR1CALM1CAMKK2TLR7PPARG
SCHEMBL650072 0.91 C5AR1 (0.41) C5AR1TLR7MEP1BALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed